Effects of Lomitapide on Carotid and Aortic Atherosclerosis

NCT02399852 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-12-15

No results posted yet for this study

Summary

Study to assess changes in carotid and aortic atherosclerosis in patients being treated with lomitapide.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

DRUG

Lomitapide

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Qing Chang, MD · Aegerion Pharmaceuticals, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-12-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02399852 on ClinicalTrials.gov